The National Osteoporosis Guideline Group's new guidelines: What is new'

Rheumatology

Volumn 48, Issue 4, 2009, Pages 327-329

  Bukhari, Marwan ^a,b  

^a ROYAL LANCASTER INFIRMARY   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCITONIN; CALCITRIOL; ETIDRONIC ACID; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID; STRONTIUM RANELATE; ZOLEDRONIC ACID;

ALCOHOL CONSUMPTION; BONE DENSITY; CALCIUM INTAKE; CREATININE CLEARANCE; DRUG EFFICACY; EDITORIAL; EXERCISE; FRACTURE; FRAGILITY FRACTURE; HEALTH PROGRAM; HUMAN; OSTEOPOROSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN INTAKE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SMOKING CESSATION; VITAMIN SUPPLEMENTATION;

AGED; AGED, 80 AND OVER; BONE DENSITY; DIPHOSPHONATES; FRACTURES, BONE; GREAT BRITAIN; GUIDELINES AS TOPIC; HUMANS; MIDDLE AGED; OSTEOPOROSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 63249087945     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken454     Document Type: Editorial

References (8)

1. Kanis JA, Brazier JE, Stevenson M, Calvert NW, Lloyd Jones M. Treatment of established osteoporosis: A systematic review and cost-utility analysis. Health Technol Assess 2002;6:1-146.
2. Royal College of Physicians. Osteoporosis: Clinical guidelines for the prevention and treatment. London: Royal College of Physicians, 1999.
3. Royal College of Physicians and Bone and Tooth Society of Great Britain. Update on pharmacological interventions and an algorithm for management. London: Royal College of Physicians, 2000.
4. Royal College of Physicians. Glucocorticoid-induced osteoporosis. Guidelines on prevention and treatment. Bone and Tooth Society of Great Britain, National Osteoporosis Society and Royal College of Physicians. London: Royal College of Physicians 2002.
5. National Institute for Health and Clinical Excellence. Appraisal Consultation Document. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. London: NICE, 2007.
6. National Institute for Health and Clinical Excellence. Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. London: NICE, 2007.
7. National Institute for Health and Clinical Excellence. Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. London: NICE, 2007.
8. Kanis JA; on behalf of the World Health Organization Scientific Group (2007). Assessment of osteoporosis at the primary health-care level. Technical Report. University of Sheffield, UK: WHO Collaborating Centre, 2008.